Research advances in sodium-glucose co-transporter 2 inhibitor in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease
10.3969/j.issn.1001-5256.2019.12.037
- VernacularTitle:钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并非酒精性脂肪肝病的研究进展
- Author:
Miaomiao XUE
1
;
Xueping LI
;
Y LI
Author Information
1. Clinical Medical College, Xi’an Medical University, Xi’an 710021, China
- Publication Type:Research Article
- Keywords:
diabetes mellitus, type 2;
nonalcoholic fatty liver disease;
sodium-glucose co-transporter-2 inhibitor
- From:
Journal of Clinical Hepatology
2019;35(12):2812-2816
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a common complication of type 2 diabetes mellitus (T2DM) and can progress to liver cirrhosis and even hepatocellular carcinoma, but there are still no effective pharmacotherapies for NAFLD at present. Sodium-glucose co-transporter 2 inhibitor (SGLT-2i) is a newly approved oral hypoglycemic agent and can effectively reduce blood glucose. Meanwhile, SGLT-2i can improve NAFLD by improving lipid accumulation and insulin resistance, exerting anti-inflammatory and anti-oxidative stress effects, reducing liver fibrosis degree, and delaying the progression to hepatocellular carcinoma. SGLT-2i also helps with the prevention of NAFLD by reducing the toxicity of high glucose, body weight, and blood uric acid and improving liver dysfunction. This article reviews the current status of T2DM with NAFLD, the mechanism of action of SGLT-2i, the effect of SGLT-2i in preventing T2DM with NAFLD, and the safety of SGLT-2i.
